| Salivary plasminogen activator alpha 1 | |||||||
|---|---|---|---|---|---|---|---|
 | |||||||
| Identifiers | |||||||
| Organism | |||||||
| Symbol | PLAT | ||||||
| Alt. symbols | BAT-PA; DSPA-5 | ||||||
| ATC code | B01 | ||||||
| CAS number | 145137-38-8 | ||||||
| DrugBank | |||||||
| Entrez | 112321404 | ||||||
| HomoloGene | 717 | ||||||
| PDB | 1A5I | ||||||
| RefSeq (mRNA) | XM_024578803.1 | ||||||
| RefSeq (Prot) | XP_024434571.1 | ||||||
| UniProt | P98119 | ||||||
| Other data | |||||||
| EC number | 3.4.21.68 | ||||||
| Chromosome | Unplaced: 1.98 - 2.01 Mb | ||||||
| |||||||
Desmoteplase is a novel, highly fibrin-specific "clot-busting" (thrombolytic) drug in development that reached phase III clinical trials. The Danish pharmaceutical company, Lundbeck, owns the worldwide rights to Desmoteplase. In 2009, two large trials (DIAS-3 and DIAS-4) were started to test it as a safe and effective treatment for patients with acute ischaemic stroke. After disappointing results in DIAS-3, DIAS-4 was terminated, and in December 2014 Lundbeck announced that they would stop the development of desmoteplase.[1]
Desmoteplase is a recombinant form of the alpha-1 isoform of DSPA (Desmodus rotundus salivary plasminogen activator).